Next Article in Journal
Comment from the Editor of the Special Issue: “Lung Disease on COPD, Asthma, Bronchiectasis, Lung Cancer Screening, IPF”
Next Article in Special Issue
Impaired HDL Metabolism Links GlycA, A Novel Inflammatory Marker, with Incident Cardiovascular Events
Previous Article in Journal
LABAs and p38MAPK Inhibitors Reverse the Corticosteroid-Insensitivity of IL-8 in Airway Smooth Muscle Cells of COPD
Previous Article in Special Issue
Anti-ApoA-1 IgGs in Familial Hypercholesterolemia Display Paradoxical Associations with Lipid Profile and Promote Foam Cell Formation
Open AccessReview

Cross-Talk between Lipoproteins and Inflammation: The Role of Microvesicles

1
Cardiovascular Program ICCC, Institut de Recerca Hospital Santa Creu i Sant Pau—IIB Sant Pau, Sant Antoni Maria Claret, 167, 08025 Barcelona, Spain
2
CIBER Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2019, 8(12), 2059; https://doi.org/10.3390/jcm8122059
Received: 25 October 2019 / Revised: 18 November 2019 / Accepted: 20 November 2019 / Published: 22 November 2019
Atherothrombosis is the principal underlying cause of cardiovascular disease (CVD). Microvesicles (MV) are small blebs originated by an outward budding at the cell plasma membranes, which are released in normal conditions. However, MV release is increased in pathophysiologic conditions such as CVD. Low density lipoprotein (LDL) and MV contribute to atherothrombosis onset and progression by promoting inflammation and leukocyte recruitment to injured endothelium, as well as by increasing thrombosis and plaque vulnerability. Moreover, (oxidized)LDL induces MV release and vice-versa, perpetuating endothelium injury leading to CVD progression. Therefore, MV and lipoproteins exhibit common features, which should be considered in the interpretation of their respective roles in the pathophysiology of CVD. Understanding the pathways implicated in this process will aid in developing novel therapeutic approaches against atherothrombosis. View Full-Text
Keywords: microvesicles; inflammation; lipoproteins; LDL cholesterol; microparticles; cardiovascular disease; platelets; endothelial cells; leukocytes; atherothrombosis microvesicles; inflammation; lipoproteins; LDL cholesterol; microparticles; cardiovascular disease; platelets; endothelial cells; leukocytes; atherothrombosis
Show Figures

Graphical abstract

MDPI and ACS Style

Chiva-Blanch, G.; Badimon, L. Cross-Talk between Lipoproteins and Inflammation: The Role of Microvesicles. J. Clin. Med. 2019, 8, 2059.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop